阿托伐他汀对大鼠心肌缺血再灌注损伤保护作用的研究

Protective effect of atorvastatin on myocardial ischemia reperfusion injury in rats

目的:探讨阿托伐他汀预处理对大鼠心肌缺血再灌注损伤(MIRI)的保护作用。方法:将20周龄的Wistar大鼠175只随机分为三组:假手术组(n=55)、缺血再灌注组(n=60)、阿托伐他汀组(n=60)。在连续空腹灌胃7d后构建大鼠MIRI模型,测量比较三组大鼠血清乳酸脱氢酶(LDH)、肌酸激酶(CK)、超敏C反应蛋白(hsCRP)水平的差异,再连续灌胃28d后测量比较三组大鼠左、右心室重量及室间隔厚度的差异。结果:与假手术组比较,缺血再灌注180min后缺血再灌注组、阿托伐他汀组LDH[(583.15±73.16)U/L比(1537.67±280.73)U/L比(1035.07±137.92)U/L]、CK[(932.72±62.82)U/L比(2872.45±136.3)U/L比(2434.07±192.81)U/L]、hsCRP[(20.98±1.86)mg/L比(48.39±1.31)mg/L比(40.29±2.33)mg/L]水平显著升高,但阿托伐他汀组的显著低于缺血再灌注组(P<0.05或<0.01)。与假手术组比较,缺血再灌注28d后缺血再灌注组、阿托伐他汀组左室相对重量[(1.21±0.17)mg/g比(1.94±0.33)mg/g比(1.53±0.35)mg/g]、右室相对重量[(0.16±0.12)mg/g比(0.39±1.21)mg/g比(0.27±0.07)mg/g]、室间隔厚度[(1.26±0.35)mm比(2.03±0.38)mm比(1.65±0.38)mm]显著增加,但阿托伐他汀组的显著低于缺血再灌注组(P均<0.01)。结论:阿托伐他汀预处理能够显著减轻心肌缺血再灌注损伤,改善心室重构。

Objective： To explore protective effect of atorvastatin preconditioning on myocardial ischemia reperfusion injury （MIRI） in rats. Methods： A total of 175 20-week old Wistar rats were randomly divided into sham operation group （n = 55）, ischemia/reperfusion （I/R） group （n = 60） and atorvastatin group （n = 60）. MIRI model in rat was established after 7d continuous fasting gavage. Levels of lactate dehydrogenase （LDH）, crcatine kinase （CK） and high sensitive C reactive protein （hsCRP） were measured and compared among three groups; after another 28d continuous gavagc, left and right ventricular mass and interventricular septal thickness （IVST） were compared among three groups. Results： Compared with sham operation group on 180min after I/R, there were significant rise in levels of LDH [ （583.15 ± 73.16） U/L vs. （1537. 67 ± 280. 73） U/L vs. （1035. 07 ± 137. 92） U/L], CK [ （932. 72 ± 62.82） U/L vs. （2872.45 ± 136. 3） U/L vs. （2434. 07 ± 192. 81） U/L] and hsCRP [ （20. 98 ± 1.86） mg/L vs. （48. 39 ± 1.31） mg/L vs. （40.29 ± 2. 33） mg/L] in I/ R group and atorvastatin group, but those of atorvastatin group were significantly lower than those of I/R group （P〈0.05 or 〈0. 01）. Compared with sham operation group on 28d after I/R, there were significant rise in left ventricular relative mass [ （1.21 ± 0. 17） mg/g vs. （1.94 ± 0. 33） mg/g vs. （1.53 ± 0. 35） mg/g], right ventricular relative mass [ （0.16 ± 0. 12） mg/g vs. （0.39 ± 1.21） mg/g vs. （0. 27 ± 0.07） mg/g] and IVST [ （1.26 ± 0. 35） mm vs. （2. 03 ± 0. 38） mm vs. （1.65 ± 0.38） mm] in I/R group and atorvastatin group, but those of atorvastatin group were significantly lower than those of I/R group, P 〈0.01 all. Conclusion： Atorvastatin preconditioning can significantly relieve myocardial ischemia reperfusion injury and improve ventricular remodeling.